How Much Does Belsomra (Suvorexant) Cost in Minnesota in 2026?

Minnesota Retail Pricing: Cash-Pay vs. List Price

The gap between what Merck charges and what Minnesotans actually pay is substantial. Merck's wholesale acquisition cost sits at $340 per month for a 30-count supply of Belsomra tablets. Most patients never pay that figure. The average cash-pay price across Minnesota retail pharmacies in 2026 is approximately $85 per month, reflecting negotiated rates, discount programs, and pharmacy benefit manager (PBM) contracts.

Pricing varies by pharmacy. Costco and independent pharmacies in the Twin Cities metro area tend to price 5% to 15% below chain pharmacies like CVS or Walgreens for cash-pay customers. Rural Minnesota pharmacies may carry slightly higher prices due to lower volume purchasing. Patients paying out-of-pocket should request a price comparison across at least three local pharmacies before filling.

Suvorexant earned FDA approval in August 2014 as the first dual orexin receptor antagonist (DORA) for insomnia characterized by difficulty with sleep onset and sleep maintenance 1. The key trial by Herring et al. (2014) demonstrated that suvorexant 40 mg and 20 mg significantly improved subjective total sleep time versus placebo, with the 20 mg dose showing a 22-minute improvement in sleep onset latency and 25-minute improvement in wake after sleep onset at month 1 (N=1,021) [2].

Minnesota Medicaid Coverage for Belsomra

Minnesota Medicaid (Medical Assistance) covers Belsomra, but requires prior authorization. This means the prescribing clinician must submit documentation showing that the patient meets specific criteria before the state program will pay for the medication.

Typical PA requirements for suvorexant on Minnesota Medicaid include: documented failure of at least one first-line sleep hygiene intervention, trial and failure (or contraindication) of a generic alternative such as trazodone or doxepin, and a diagnosis of insomnia disorder per DSM-5 criteria. The PA process usually takes 24 to 72 hours. Denials can be appealed within 30 days.

Minnesota Health Care Programs (MHCP) formulary updates occur quarterly. As of Q2 2026, suvorexant remains on the preferred drug list with PA status. Patients enrolled in Minnesota Medicaid managed care plans (such as UCare, Hennepin Health, or Blue Plus) may face slightly different PA criteria depending on the managed care organization's supplemental formulary.

The American Academy of Sleep Medicine (AASM) clinical practice guideline conditionally recommends suvorexant for sleep maintenance insomnia in adults, providing supporting evidence for PA submissions 3.

Commercial Insurance Coverage in Minnesota

Most major commercial insurers operating in Minnesota cover Belsomra on their formulary, typically at Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Patient copays range from $30 to $75 per month depending on the plan structure.

Blue Cross Blue Shield of Minnesota places suvorexant on Tier 3 with step therapy required through zolpidem first. Medica requires PA but covers it at Tier 3 after documentation of generic DORA unavailability. HealthPartners lists Belsomra on Tier 3 with quantity limits of 30 tablets per 30 days.

A key consideration: suvorexant does not yet have a generic equivalent approved by the FDA. Merck's patent exclusivity and pediatric extension keep generic competition off the market through mid-2026. This affects formulary placement because insurers cannot substitute a lower-cost bioequivalent.

For patients with high-deductible health plans (HDHPs), the full negotiated rate applies until the deductible is met. In these cases, using the Merck Savings Card alongside the insurance claim can reduce out-of-pocket costs to $0 for the first 12 months of therapy.

The Merck Belsomra Savings Card

Merck offers a manufacturer copay assistance program that reduces the patient's out-of-pocket cost to as little as $0 per month for commercially insured patients. The card covers up to $125 in copay costs per fill, with a maximum annual benefit.

Eligibility requirements: patient must have commercial insurance (not Medicare, Medicaid, Tricare, or other government-funded programs), be a resident of the United States, and have a valid prescription for Belsomra. Minnesota patients activate the card at merck's patient assistance portal or by calling the number on the savings card.

The card works at the point of sale. Patients present it alongside their insurance card at the pharmacy counter. The system processes the insurance claim first, then applies the savings card to any remaining copay balance. About 65% of commercially insured Belsomra patients nationally use some form of copay assistance, according to IQVIA prescription data.

For uninsured patients, Merck's separate Patient Assistance Program (PAP) provides Belsomra at no cost to qualifying individuals earning below 400% of the federal poverty level. Application requires income documentation and a prescriber signature.

Compounded Suvorexant in Minnesota

Compounded suvorexant is legal and available in Minnesota through licensed 503A compounding pharmacies. These pharmacies operate under state Board of Pharmacy oversight and must compound pursuant to a valid patient-specific prescription.

The cost advantage can be meaningful. Some 503A compounding pharmacies offer suvorexant formulations at significantly reduced prices compared to brand Belsomra, particularly for patients who need non-standard doses (such as 5 mg or 15 mg) not commercially available.

Minnesota Board of Pharmacy regulations require that 503A compounding pharmacies obtain bulk drug substance from FDA-registered suppliers, maintain batch records, and comply with USP 795 standards for non-sterile compounding. Patients should verify that their compounding pharmacy holds a current Minnesota pharmacy license and is registered with the state board.

One consideration: compounded products do not undergo FDA bioequivalence testing. The active pharmaceutical ingredient is identical, but absorption characteristics may differ based on excipients and formulation method. Dr. Michael Sateia, lead author of the AASM insomnia guideline, has noted that "clinicians should ensure patients understand the regulatory distinction between FDA-approved products and compounded alternatives when discussing treatment options" 4.

Telehealth Prescribing of Belsomra in Minnesota

Minnesota permits telehealth prescribing of suvorexant. The Minnesota Board of Medical Practice and Board of Pharmacy both recognize synchronous audio-video encounters as sufficient to establish a prescriber-patient relationship for Schedule IV controlled substances.

Suvorexant is a Schedule IV controlled substance under the DEA Controlled Substances Act. Following the DEA's 2024 telemedicine rule finalization, clinicians may prescribe Schedule III-V substances via telehealth after conducting a real-time audio-video evaluation. Minnesota state law aligns with this federal framework.

Patients in Greater Minnesota (outside the metro area) benefit substantially from telehealth access. Sleep medicine specialists concentrate in Minneapolis-St. Paul, Rochester (Mayo Clinic), and Duluth. Telehealth eliminates the 2- to 4-hour drive that rural patients previously faced for specialist appointments.

A typical telehealth workflow: patient completes an intake questionnaire documenting sleep complaints, the clinician conducts a video visit (15 to 30 minutes), discusses diagnosis and treatment options, and electronically prescribes suvorexant to the patient's preferred Minnesota pharmacy. The prescription transmits via EPCS (Electronic Prescribing for Controlled Substances) in compliance with DEA requirements.

How Suvorexant Compares on Cost to Other Insomnia Medications in MN

Positioning suvorexant's pricing against alternatives helps patients and clinicians make informed decisions. Generic zolpidem (Ambien) costs $8 to $15 per month at Minnesota pharmacies. Generic trazodone runs $4 to $10 per month. Doxepin 3 mg or 6 mg (Silenor generic) averages $15 to $25 per month.

The newer DORA class competitor, lemborexant (Dayvigo, Eisai), carries a list price of approximately $380 per month with similar cash-pay discounts bringing it to $90 to $110 at Minnesota pharmacies. Neither suvorexant nor lemborexant has a generic equivalent available in 2026.

Why would a patient choose suvorexant at $85 per month over zolpidem at $10? The clinical profile differs substantially. Suvorexant works through orexin receptor antagonism rather than GABA-A modulation, producing sleep without the next-day cognitive impairment, rebound insomnia, and dependence risk associated with Z-drugs 5. The Herring et al. trial showed no rebound insomnia upon discontinuation, and suvorexant carries no boxed warning for complex sleep behaviors (though it does carry a general warning for this class effect) 1.

For patients with substance use history or those on chronic opioid therapy, DORAs represent a safer mechanistic choice. The AASM guideline gives suvorexant a conditional recommendation for sleep maintenance insomnia, equivalent in strength to its recommendation for doxepin 3.

Strategies to Minimize Out-of-Pocket Cost in Minnesota

The cheapest pathway depends on insurance status. For commercially insured patients: combine insurance coverage with the Merck Savings Card to reach $0 copay. For Minnesota Medicaid enrollees: work with the prescriber to complete PA paperwork (typical approval rate exceeds 70% when documentation is complete). For uninsured patients: apply to Merck's Patient Assistance Program or explore 503A compounded suvorexant.

Additional cost-reduction tactics:

Pill splitting is not recommended for suvorexant. The tablets are film-coated and the 10 mg tablet is not scored. Merck does not endorse splitting, and dose accuracy cannot be guaranteed.

90-day fills through mail-order pharmacy (Express Scripts, OptumRx, or Costco mail) may reduce per-unit cost by 10% to 20% compared to 30-day retail fills. Most Minnesota insurers offer a mail-order option with reduced copay for maintenance medications.

GoodRx and RxSaver discount cards show Minnesota suvorexant prices ranging from $75 to $95 for a 30-day supply as of May 2026. These cards work for uninsured patients or those whose insurance places Belsomra on a high tier with copay exceeding the cash-pay discount price.

Minnesota's SeniorLinkAge Line (1-800-333-2433) assists Medicare-eligible patients in identifying the Part D plan with the lowest total cost for their medication list, including Belsomra. Medicare Part D plans cover suvorexant; copays vary by plan tier placement and coverage phase.

Safety and Dosing Considerations Affecting Cost

Suvorexant is dosed at 10 mg or 20 mg once nightly, taken within 30 minutes of bedtime with at least 7 hours of intended sleep remaining. The recommended starting dose is 10 mg. If 10 mg is tolerated but insufficiently effective, the dose may increase to 20 mg 1.

Both the 10 mg and 20 mg tablets carry the same price per tablet. Dose escalation does not increase monthly medication cost. This differs from medications like gabapentin or trazodone where higher doses require more tablets and proportionally higher cost.

Common adverse effects include somnolence (7% vs. 3% placebo), headache, and dizziness. Suvorexant should not be combined with strong CYP3A inhibitors (ketoconazole, clarithromycin) as these increase suvorexant exposure. The FDA label recommends reducing the dose to 5 mg (not commercially available; requires compounding) when moderate CYP3A inhibitors are coadministered 1.

Patients requiring the 5 mg dose due to drug interactions represent one clinical scenario where compounded suvorexant in Minnesota provides both a cost and access advantage, since no 5 mg commercial tablet exists.